• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

组织学分级对滤泡性淋巴瘤结局的影响:在不断发展的疾病分类和治疗背景下,对 SEER 数据库中患者的分析。

The impact of histological grade on outcomes in follicular lymphoma: An analysis of patients in the SEER database in the context of evolving disease classification and treatment.

机构信息

Pathology Section, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

Clinical Biostatistics Program, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

出版信息

Br J Haematol. 2022 Dec;199(5):696-706. doi: 10.1111/bjh.18404. Epub 2022 Aug 16.

DOI:10.1111/bjh.18404
PMID:35973829
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9691538/
Abstract

Currently, there is no convincing evidence that the grade of follicular lymphoma (FL) impacts patient outcome. We correlated grades in 33 925 patients with nodal FL during 1992-2018 in the SEER database with disease-specific survival (DSS) and overall survival (OS). Patients with FL grade 3 had lower DSS and OS as compared to FL grades 1-2. During 1992-2005, the 10-year DSS for patients with FL grades 3 and grades 1-2 were 68.6%, and 71.4%, respectively, and in 2006-2018, they were 77.7% and 82.6%, respectively. The 10-year OS estimates in 1992-2005 were 49.9% and 54.2% for grade 3 and grades 1-2 respectively, and in 2006-2018, they were 59.1% and 63.5% for grade 3 and grades 1-2, respectively. After adjustment for stage and age, the hazard ratios for death due to FL and death from any cause for patients with FL grade 3 during 1992-2005 were 1.09 (1.02-1.16) and 1.07 (1.02-1.12), respectively, compared to FL grades 1-2; and during 2006-2018, the hazard ratios for death due to FL and death from any cause for patients with FL grade 3 were 1.34 (1.22-1.45) and 1.16 (1.10-1.23), respectively compared to FL grades 1-2. The grade of FL is an important determinant of disease biology.

摘要

目前,尚无令人信服的证据表明滤泡性淋巴瘤(FL)的分级会影响患者的预后。我们将 1992 年至 2018 年间 SEER 数据库中 33925 例结内滤泡性淋巴瘤患者的分级与疾病特异性生存率(DSS)和总生存率(OS)相关联。FL 3 级患者的 DSS 和 OS 低于 FL 1-2 级。1992 年至 2005 年,FL 3 级和 1-2 级患者的 10 年 DSS 分别为 68.6%和 71.4%,而在 2006 年至 2018 年,它们分别为 77.7%和 82.6%。1992 年至 2005 年,FL 3 级和 1-2 级患者的 10 年 OS 估计值分别为 49.9%和 54.2%,而在 2006 年至 2018 年,它们分别为 59.1%和 63.5%。在调整了分期和年龄后,1992 年至 2005 年 FL 3 级患者因 FL 死亡和因任何原因死亡的风险比分别为 1.09(1.02-1.16)和 1.07(1.02-1.12),而与 FL 1-2 级相比;而在 2006 年至 2018 年,FL 3 级患者因 FL 死亡和因任何原因死亡的风险比分别为 1.34(1.22-1.45)和 1.16(1.10-1.23)。FL 的分级是疾病生物学的一个重要决定因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a11f/9691538/950d2b774d1c/nihms-1830367-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a11f/9691538/e52fa0ad9245/nihms-1830367-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a11f/9691538/505ae25c3299/nihms-1830367-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a11f/9691538/950d2b774d1c/nihms-1830367-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a11f/9691538/e52fa0ad9245/nihms-1830367-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a11f/9691538/505ae25c3299/nihms-1830367-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a11f/9691538/950d2b774d1c/nihms-1830367-f0003.jpg

相似文献

1
The impact of histological grade on outcomes in follicular lymphoma: An analysis of patients in the SEER database in the context of evolving disease classification and treatment.组织学分级对滤泡性淋巴瘤结局的影响:在不断发展的疾病分类和治疗背景下,对 SEER 数据库中患者的分析。
Br J Haematol. 2022 Dec;199(5):696-706. doi: 10.1111/bjh.18404. Epub 2022 Aug 16.
2
Follicular non-Hodgkin's lymphoma: correlation between histology, pathophysiology, cytogenetic, prognostic factors, treatment, survival.滤泡性非霍奇金淋巴瘤:组织学、病理生理学、细胞遗传学、预后因素、治疗与生存之间的相关性
Rom J Morphol Embryol. 2013;54(1):71-6.
3
Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?滤泡性淋巴瘤3级的治疗结果:蒽环类药物作为一线治疗是否必要?
Br J Cancer. 2003 Jul 7;89(1):36-42. doi: 10.1038/sj.bjc.6601006.
4
Long-term outcome comparing histological grades of follicular lymphoma patients treated with immunochemotherapy as first-line therapy: A retrospective analysis from two institutions.对比滤泡性淋巴瘤患者接受一线免疫化疗治疗后组织学分级的长期疗效:来自两个机构的回顾性分析。
Eur J Haematol. 2020 Mar;104(3):198-206. doi: 10.1111/ejh.13359. Epub 2019 Dec 22.
5
Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study†.40岁及以下滤泡性淋巴瘤患者的疾病特征、治疗模式及预后:来自国家淋巴瘤关爱研究的分析†
Ann Oncol. 2015 Nov;26(11):2311-7. doi: 10.1093/annonc/mdv375. Epub 2015 Sep 11.
6
Gastrointestinal follicular lymphoma: using primary site as a predictor of survival.胃肠道滤泡性淋巴瘤:以原发部位作为生存预测指标
Cancer Med. 2016 Oct;5(10):2669-2677. doi: 10.1002/cam4.763. Epub 2016 Oct 1.
7
Follicular lymphoma grade 3: review and updates.滤泡性淋巴瘤3级:综述与更新
Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):431-5. doi: 10.1016/j.clml.2014.04.008. Epub 2014 Jun 12.
8
Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.降低强度同种异体移植作为复发/难治性一、二级滤泡性淋巴瘤首次移植方法可改善长期幸存者的预后。
Biol Blood Marrow Transplant. 2015 Dec;21(12):2091-2099. doi: 10.1016/j.bbmt.2015.07.028. Epub 2015 Aug 4.
9
The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphoma.组织学分级对滤泡性淋巴瘤大剂量治疗及自体干细胞移植结局的影响。
Bone Marrow Transplant. 2007 Dec;40(11):1039-44. doi: 10.1038/sj.bmt.1705864. Epub 2007 Oct 8.
10
Prognostic significance of histologic grade and Ki-67 proliferation index in follicular lymphoma.滤泡性淋巴瘤组织学分级和 Ki-67 增殖指数的预后意义。
Hematol Oncol. 2020 Dec;38(5):665-672. doi: 10.1002/hon.2778. Epub 2020 Sep 10.

引用本文的文献

1
Molecular landscape of distinct follicular lymphoma histologic grades: insights from genomic and transcriptome analyses.不同组织学分级滤泡性淋巴瘤的分子图谱:来自基因组和转录组分析的见解
Leukemia. 2025 Apr 15. doi: 10.1038/s41375-025-02603-9.
2
The association between radiotherapy and the prognosis of follicular lymphoma patients with different characteristics in the rituximab era: a cohort study based on Surveillance, Epidemiology and End Results.利妥昔单抗时代不同特征滤泡性淋巴瘤患者放疗与预后的关联:一项基于监测、流行病学和最终结果的队列研究
Ann Hematol. 2025 Jan;104(1):691-700. doi: 10.1007/s00277-025-06209-0. Epub 2025 Jan 24.
3

本文引用的文献

1
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.《世界卫生组织造血与淋巴组织肿瘤分类》第五版:淋巴肿瘤。
Leukemia. 2022 Jul;36(7):1720-1748. doi: 10.1038/s41375-022-01620-2. Epub 2022 Jun 22.
2
Counting mitoses: SI(ze) matters!计数有丝分裂:大小很重要!
Mod Pathol. 2021 Sep;34(9):1651-1657. doi: 10.1038/s41379-021-00825-7. Epub 2021 Jun 2.
3
Prognostic significance of histologic grade and Ki-67 proliferation index in follicular lymphoma.滤泡性淋巴瘤组织学分级和 Ki-67 增殖指数的预后意义。
Differences in clinical characteristics and outcomes between patients with grade 3a and grades 1-2 follicular lymphoma: a real-world multicenter study.
3a级与1-2级滤泡性淋巴瘤患者的临床特征及预后差异:一项真实世界的多中心研究。
Biomark Res. 2023 Feb 6;11(1):16. doi: 10.1186/s40364-023-00462-z.
Hematol Oncol. 2020 Dec;38(5):665-672. doi: 10.1002/hon.2778. Epub 2020 Sep 10.
4
Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma.苯达莫司汀-利妥昔单抗治疗后早期进展与晚期滤泡性淋巴瘤转化风险高相关。
Blood. 2019 Aug 29;134(9):761-764. doi: 10.1182/blood.2019000258. Epub 2019 Jul 12.
5
Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.在滤泡性淋巴瘤的 GALLIUM 研究中,早期疾病进展与极差的生存相关:奥滨尤妥珠单抗降低早期进展率的获益。
Haematologica. 2019 Jun;104(6):1202-1208. doi: 10.3324/haematol.2018.209015. Epub 2018 Dec 20.
6
Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2.基因表达谱分析揭示了滤泡性淋巴瘤 3A 级和 3B 级之间的密切关系,但滤泡性淋巴瘤 1 级和 2 级的表现则明显不同。
Haematologica. 2018 Jul;103(7):1182-1190. doi: 10.3324/haematol.2017.181024. Epub 2018 Mar 22.
7
Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort.组织学分级对SWOG S0016滤泡性淋巴瘤队列生存情况的影响。
Haematologica. 2018 Apr;103(4):e151-e153. doi: 10.3324/haematol.2017.175059. Epub 2018 Feb 22.
8
Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era.3级滤泡性淋巴瘤:利妥昔单抗时代的治疗结果
Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):797-803. doi: 10.1016/j.clml.2017.07.002. Epub 2017 Jul 13.
9
Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial.PRIMA 试验中,一线免疫化疗后缓解的滤泡性淋巴瘤患者发生组织学转化的风险因素和结局。
J Clin Oncol. 2016 Aug 1;34(22):2575-82. doi: 10.1200/JCO.2015.65.7163. Epub 2016 Jun 13.
10
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.苯达莫司汀-利妥昔单抗或 R-CHOP/R-CVP 一线治疗惰性 NHL 或 MCL 的随机试验:BRIGHT 研究。
Blood. 2014 May 8;123(19):2944-52. doi: 10.1182/blood-2013-11-531327. Epub 2014 Mar 3.